Product Description: SAR-020106 is an ATP-competitive, potent, and selective CHK1 inhibitor with an IC50 of 13.3 nM for human CHK1. SAR-020106 shows excellent selectivity over CHK2. SAR-020106 significantly enhances the cell killing of Gemcitabine and SN38 by 3- to 29-fold in several colon tumor lines and in a p53-dependent fashion. SAR-020106 can enhance antitumor activity with selected anticancer agents[1][2].
Applications: Cancer-Kinase/protease
Formula: C19H19ClN6O
References: [1]Walton MI, et al. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. Mol Cancer Ther. 2010;9(1):89-100./[2]Reader JC, et al. Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing. J Med Chem. 2011;54(24):8328-8342.
CAS Number: 1184843-57-9
Molecular Weight: 382.85
Compound Purity: 98.04
Research Area: Cancer
Solubility: DMSO : 5 mg/mL (ultrasonic)
Target: Checkpoint Kinase (Chk)
Deutsch
English
